Adenosine deaminase acting on RNA (ADAR) is the enzyme responsible for adenosine-to-inosine (A-to-I) RNA editing, a process ...

A particular protein deficiency that leads to liver and lung damage is currently treatable only with decades-old therapies that all have limitations. Biotech startup AIRNA is part of a field of ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today ...

These new preclinical platform data further highlight the potential of Axiomer EONs in preparation for clinical development and supporting discovery of potential new therapeutic applications. The ...

Korro Bio's lead asset is expected to enter a Phase 1/2 trial in adult A1ATD patients in the second half of 2024. Analyst writes Korro's preclinical data package, particularly in the NSG PiZ mouse ...

Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndrome Collaboration expands ProQR’s commitment to advance the ...

Inosine is a nucleoside that occurs naturally in transfer RNAs (tRNAs) and is essential for proper RNA translation. It is commonly found at the wobble position of anticodons, allowing for greater ...

Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and mice Functional effect demonstrated in mice in vivo via ...